Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
Sichuan Kelun Pharmaceutical (002422 CH)
Watchlist
78
Analysis
Health Care
•
China
Sichuan Kelun Pharmaceutical Co., Ltd. manufactures pharmaceutical products. The Company's products include large infusion products, tablets, capsules, antibiotic injection, lyophilized powder for injection, and traditional Chinese medicine.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bearish
•
The United Laboratories International Holdings Limited
•
19 Sep 2023 12:21
United Laboratories International Holdings Placement (3933.HK) - Valuation Pullback Seems Inevitable
United Lab is facing a performance decline when the dividend period of the pandemic has subsided. Weight management/veterinary drug businesses have...
Xinyao (Criss) Wang
Follow
466 Views
Share
bullish
•
Innovent Biologics Inc
•
11 Sep 2023 21:11
Innovent Biologics Placement - Has Ample Cash but the Discount Is Enticing
Innovent Biologics Inc (1801 HK) (IB) aims to raise around US$313m for R&D and marketing. In this note, we talk about the deal dynamics and run the...
Sumeet Singh
Follow
521 Views
Share
bearish
•
Zai Lab
•
11 Sep 2023 09:16
Zai Lab (9688.HK/ZLAB.US) 2022/2023Q1 - The True Colors and the Risks Behind
In the insight, we analyzed major investment logic flaws of Zai Lab. As we expected, the company's performance is not ideal. The license-in model...
Xinyao (Criss) Wang
Follow
571 Views
Share
bearish
•
Edding Group
•
24 Jul 2023 08:55
Pre-IPO Edding Group - CSO Model Is Hard to Sustain, but Business Transformation Faces Challenges
As once a leading CSO company in China, Edding’s core advantage still lies in sales capabilities. But changes in domestic policy/business...
Xinyao (Criss) Wang
Follow
309 Views
Share
bullish
•
Kelun Biotech
•
08 Jun 2023 16:23
Kelun-Biotech (科伦博泰) Pre-IPO: Thoughts on Valuation
Kelun Biotech is raising up to US$400m to list in Hong Kong. In this note we provide valuation for its core products, SKB264 and A166.
Ke Yan, CFA, FRM
Follow
461 Views
Share
Previous
1
2
3
4
5
Next
Last
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.34.5
x